Gouvernance Verastem, Inc.

VSTM

US92337C2035

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 14/08/2026			Varia. 5j.	Varia. 1 janv.
6,580 ^USD	-1,35%		-2,37%	-14,77%

11/08	Verastem, Inc. : Mizuho Securities à l'achat	ZM
06/08	Transcript : Verastem, Inc., Q2 2026 Earnings Call, Aug 06, 2026

Comité Exécutif: Verastem, Inc.

Dirigeant

Fonctions occupéesDepuis

Dan Paterson

65 ans

Chief Executive Officer	01/08/2023
President	20/06/2019

Jonathan Pachter

68 ans

Chief Tech/Sci/R&D Officer

01/07/2011

Daniel Calkins

39 ans

Director of Finance/CFO

31/10/2022

Colleen Mockbee

General Counsel

John Hayslip

Chief Tech/Sci/R&D Officer

18/04/2024

Julissa Viana

Investor Relations Contact	05/03/2024
Public Communications Contact	05/03/2024

Composition du Conseil d'Administration: Verastem, Inc.

Administrateur

ComitésDepuis

John Johnson

68 ans

Compensation Committee
Governance Committee
Nominating Committee

Eric Rowinsky

69 ans

Compensation Committee	01/01/2010
Governance Committee	01/01/2010
Nominating Committee
Nominating Committee Chair

Anil Kapur

56 ans

Audit Committee	15/05/2023
Compensation Committee	20/10/2022
Governance Committee
Nominating Committee

Brian Stuglik

66 ans

Compensation Committee	17/05/2018
Compensation Committee Chair	01/01/2022

Michael Kauffman

62 ans

Compensation Committee	04/06/2025
Audit Committee	04/06/2025

Karin Tollefson

59 ans

Governance Committee	15/05/2023
Nominating Committee	15/05/2023

Michael Bailey

60 ans

Governance Committee Chair

01/05/2022

Michelle Robertson

59 ans

Audit Committee Chair

15/11/2021

Dan Paterson

65 ans

Director/Board Member

01/08/2023

Paul Bunn

81 ans

Director/Board Member	24/06/2021
Independent Dir/Board Member	24/06/2021

Dernières Nominations: Verastem, Inc.

26/05	Verastem, Inc. annonce des changements au sein de son conseil d'administration	CI
07/05	Verastem, Inc. nomme Daniel Lyons au poste de Chief Commercial Officer	CI
26/02	Akari Therapeutics plc nomme le Dr Prafulla Gokhale au sein de son conseil consultatif scientifique	CI
15/12	Verastem Oncology annonce des changements au sein de sa direction	CI
15/01/25	Verastem nomme Matthew E. Ros au poste de directeur de l'exploitation	MT
15/01/25	Verastem Oncology nomme Matthew E. Ros au poste de directeur des opérations	CI
18/04/24	Verastem nomme John Hayslip au poste de médecin-chef	MT

Plus d'Actualités

Anciens Dirigeants et Administrateurs: Verastem, Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Matthew Ros

Chief Operating Officer

15/01/2025

15/12/2025

David Mitchell

General Counsel

26/10/2023

01/04/2024

Lisa Buffington

Public Communications Contact

01/10/2020

31/01/2024

Lesley Solomon

Director/Board Member	24/06/2021	15/05/2023
Independent Dir/Board Member	24/06/2021	15/05/2023

Robert Gagnon

Director of Finance/CFO	28/08/2018	31/10/2022
Director/Board Member	13/12/2022	21/05/2026

Ajay Munshi

Investor Relations Contact

Timothy Barberich

Director/Board Member	10/03/2014	31/03/2022
Independent Dir/Board Member	10/03/2014	31/03/2022

Gina Consylman

Director/Board Member	17/10/2018	15/11/2021
Independent Dir/Board Member	17/10/2018	15/11/2021

Louis J. Denis

Chief Tech/Sci/R&D Officer

22/09/2021

Bruce Wendel

Director/Board Member	14/06/2016	18/05/2021
Independent Dir/Board Member	14/06/2016	18/05/2021

Frank Neumann

Chief Tech/Sci/R&D Officer

06/01/2021

20/01/2021

John Doyle

Investor Relations Contact

01/02/2018

01/12/2020

Robert Morgan

Corporate Officer/Principal

20/02/2019

01/06/2020

Alison Lawton

Director/Board Member	26/11/2012	19/05/2020
Independent Dir/Board Member	26/11/2012	19/05/2020

Madelyn Zeylikman

General Counsel	01/11/2019	01/04/2020
Corporate Secretary	01/11/2019	01/04/2020

Amy Pernell Cavers

Corporate Officer/Principal

20/02/2019

01/03/2020

Sean Flynn

General Counsel	01/06/2018	01/10/2019
Corporate Secretary	01/06/2018	01/10/2019

Shawn Leland

Corporate Officer/Principal

01/09/2017

01/08/2019

Brian Sullivan

Public Communications Contact	01/11/2010	-
Corporate Officer/Principal	01/11/2010	01/08/2019

Kirk Taylor

Corporate Officer/Principal

18/10/2018

01/08/2019

Robert M. Forrester

Director/Board Member	09/07/2013	20/06/2019
Chief Executive Officer	09/07/2013	20/06/2019
Chief Operating Officer	24/03/2011	16/05/2013
Director of Finance/CFO	24/03/2011	16/05/2013
President	22/01/2013	20/06/2019

Erin S. Cox

Public Communications Contact

20/02/2019

01/06/2019

Steven Bloom

Corporate Officer/Principal

01/03/2014

01/04/2019

Joseph Lobacki

Corporate Officer/Principal

04/01/2018

01/01/2019

Peter A. Pellegrino

Comptroller/Controller/Auditor	01/01/2018	01/01/2019
Treasurer	01/01/2018	01/01/2019

Tiffany Burt

Sales & Marketing

01/09/2017

01/12/2018

Mahesh Padval

Corporate Officer/Principal

01/01/2016

01/11/2018

Joseph Chiapponi

Comptroller/Controller/Auditor	18/04/2016	10/07/2017
Director of Finance/CFO	18/04/2016	10/07/2017
Corporate Officer/Principal	10/07/2017	01/11/2018
Treasurer	18/04/2016	10/07/2017

S. Phanstiel

Director/Board Member	19/09/2012	16/10/2018
Independent Dir/Board Member	19/09/2012	16/10/2018

NgocDiep Le

Chief Tech/Sci/R&D Officer	11/10/2017	12/10/2018
Chief Tech/Sci/R&D Officer	-	-

Julie Feder

Director of Finance/CFO

10/07/2017

01/06/2018

Michael Ferraresso

Corporate Officer/Principal

24/01/2017

01/11/2017

Paul Friedman

Director/Board Member	12/05/2014	27/04/2017
Independent Dir/Board Member	14/04/2015	27/04/2017

Gregory Berk

Chief Tech/Sci/R&D Officer

15/04/2016

19/01/2017

Stephen Sherwin

Director/Board Member	06/03/2013	13/06/2016
Independent Dir/Board Member	21/10/2013	13/06/2016

Henri A. Termeer

Director/Board Member	13/06/2011	13/06/2016
Independent Dir/Board Member	13/06/2011	13/06/2016

John Green

Director of Finance/CFO

14/05/2013

15/04/2016

Louis Vaickus

Chief Tech/Sci/R&D Officer

15/04/2016

Jessica Christo

Corporate Officer/Principal

01/03/2013

01/12/2015

Joanna Horobin

Chief Tech/Sci/R&D Officer

01/09/2012

01/07/2015

Richard Aldrich

Director/Board Member	04/08/2010	16/09/2014
Founder	04/08/2010	16/09/2014
Independent Dir/Board Member	04/08/2010	16/09/2014

Monica Singh Kleinman

General Counsel

01/03/2014

Paul Brannelly

Director of Finance/CFO	19/11/2010	06/04/2012
Corporate Officer/Principal	06/04/2012	01/05/2013
Corporate Secretary	01/11/2010	01/05/2013
Treasurer	01/11/2010	01/05/2013

Stephen Kraus

Director/Board Member	19/11/2010	27/11/2012
Independent Dir/Board Member	01/11/2010	27/11/2012

Ansbert Gadicke

Director/Board Member	19/11/2010	27/11/2012
Independent Dir/Board Member	01/11/2010	27/11/2012

John Clarke

Director/Board Member	01/11/2010	-
Independent Dir/Board Member	01/11/2010	-

Eric Lander

Founder

04/08/2010

Robert F. Weinberg

Founder

04/08/2010

Piyush Gupta

Director/Board Member	13/09/2011	04/11/2011
Founder	04/08/2010	-

Michelle Dipp

Founder

04/08/2010

Satish Jindal

Chief Operating Officer	04/08/2010	24/03/2011
Founder	04/08/2010	-
Corporate Officer/Principal	24/03/2011	13/09/2011
President	04/08/2010	24/03/2011

Christoph Westphal

Chief Executive Officer	-	-
Chairman	04/08/2010	-
Founder	04/08/2010	-

Nadeem Mirza

Corporate Officer/Principal

Stephen R. Jamieson

Chief Tech/Sci/R&D Officer

Kevin T. Sprott

Corporate Officer/Principal

Amy C. Cavers

Corporate Officer/Principal

Virginia Kelly

Corporate Officer/Principal

Lara Meisner

General Counsel

Jessie Lin

Public Communications Contact

Jean George

Director/Board Member

John Green

Director of Finance/CFO

Ian W. Flinn

Corporate Officer/Principal

Peter Elliott

Chief Tech/Sci/R&D Officer

19/11/2010

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	15
Femme	4

Dont comité exécutif

Homme	4
Femme	2

Dont Administrateurs

Homme	9
Femme	1

Verastem, Inc. est une société biopharmaceutique spécialisée dans le développement de médicaments en phase avancée, qui se consacre au développement et à la commercialisation de nouveaux traitements visant à améliorer la qualité de vie des patients atteints de cancers liés au sarcome Ras (RAS) ou à la voie de signalisation des kinases activées par les mitogènes (MAPK). Ses produits candidats comprennent l'avutométinib et le défactinib. L'avutométinib est un inhibiteur oral de la voie RAF/MEK qui inhibe les activités des kinases MEK1/2 et induit la formation de complexes inactifs entre MEK et le proto-oncogène A-Raf, potentiellement une sérine/thréonine kinase (ARAF), la sérine/thréonine kinase du proto-oncogène B-Raf (BRAF) et la sérine/thréonine kinase du proto-oncogène C-Raf, créant ainsi une réponse antitumorale grâce à une inhibition maximale de la voie RAS/MAPK. Le défactinib est un inhibiteur sélectif oral de la FAK et de la tyrosine kinase riche en proline (PYK2), les deux membres de la famille des kinases d'adhésion focale, qui sont des protéines tyrosine kinases non réceptrices. La FAK et la PYK2 intègrent les signaux provenant des récepteurs de l'intégrine et des facteurs de croissance afin de réguler la prolifération cellulaire.

Employés

102

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société